Research programme: bispecific and trispecific antibodies - Covagen

Drug Profile

Research programme: bispecific and trispecific antibodies - Covagen

Alternative Names: Bispecific FynomAbs - Covagen; COVA-208; FynomAbs - Covagen; Polyspecific FynomAbs - Covagen; Trispecific FynomAbs - Covagen

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Covagen
  • Developer Covagen; Mitsubishi Tanabe Pharma Corporation; Tanabe Research Laboratories USA
  • Class Bispecific antibodies; Trispecific antibodies
  • Mechanism of Action Cytokine inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Preclinical Ankylosing spondylitis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Switzerland (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in Switzerland (Parenteral)
  • 25 Aug 2014 Cilag GmbH International acquires Covagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top